Official Title
Genetics and Genomics of Aspirin Exacerbated Respiratory Disease (AERD)
Brief Title
Genetics and Genomics of Aspirin Exacerbated Respiratory Disease (AERD)
Protocol ID
NCT04261582
Lead Sponsor
National Jewish Health
Brief Summary
Aspirin Exacerbated Respiratory Disease (AERD) is a relatively homogeneous disease
characterized by adult-onset severe asthma, development of non-cancerous growths in the
nasal canal (i.e. nasal polyps) and aspirin allergy. The cause of AERD is unknown,
although likely results from environmental insults in combination with genetic
susceptibility. AERD disease homogeneity increases the possibility of discovering
narrowly-defined genetic contributors, and makes it an ideal population to study the
genetic and epigenetic changes that cause asthma. Researchers recently discovered that
gene expression of epithelial growth and repair (EGR) genes are substantially decreased
in bronchial airway epithelial cells of severe asthmatics compared to less severe
asthmatics and healthy controls. This new finding indicates that epithelial integrity and
related processes may be of primary importance to the development of severe asthma, and
potentially the severe asthma subtype, AERD. This finding was later supported in a
subsequent lab model, which showed that blocking a central epithelial repair and
differentiation gene, human epidermal growth factor receptor 2 (ERBB2), decreased healing
time of bronchial epithelial cells after injury. Thus, the objective of the proposed
study is to determine whether EGR gene are also down-regulated in AERD, a homogeneous
severe asthma subtype. As an extension, the researchers will also determine whether
genetic mutations and/or epigenetic changes relate to and potentially explain this
down-regulation of EGR genes. Specifically, the researchers plan to obtain gene
expression of freshly brushed nasal airway epithelial cells of 140 AERD patients, 70
non-aspirin sensitive asthma patients, and 35 healthy controls, noting that nasal
epithelial gene expression has recently been shown to mirror lung epithelial changes in
asthmatic airways. Swabbing the nasal canal for epithelial cells allows to evaluate
airway epithelial cell gene expression non-invasively. Our experimental design contrasts
AERD gene expression profiles against healthy controls, and determines whether EGR genes
are depressed in AERD relative to health controls. As a corollary, the researchers look
to discover an AERD-specific gene expression profile which may one-day aid in diagnosis
and expand current knowledge of disease mechanisms. As an extension, the researchers will
correlate gene expression changes, specifically any finding of down-regulated EGR genes,
with methylation changes (i.e. epigenetic changes) and genetic mutations.
Study Period
Enrollment Count
245 participants
Eligibility Criteria
Inclusion Criteria:
- Physician diagnosis of asthma
- Physician diagnosis of chronic nasal disease featuring nasal polyps
- Sensitivity to aspirin verified by an aspirin provocative challenge in clinic
- Healthy control participant
Exclusion Criteria:
- Active smoking
- Pregnancy
- History of greater than or equal to 10 pack-years of smoking
- Any significant comorbid conditions that could inadvertently interfere with study
results
- Conditions that require bursts of oral corticosteroids
- Other significant lung diseases
- Other disease in the view of the investigator prohibits participation in the study
Filters
Aspirin Exacerbated Respiratory Disease
Aspirin-Sensitive Asthma
Nasal Polyps
SUSPENDED
ADULT
OLDER_ADULT